Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

M. Lia Palomba, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, Jonathon B. Cohen, Krish Patel, Jennifer Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael L. Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. TamJohn F. Seymour, Joanna M. Rhodes, Julie M. Vose, Matthew McKinney, James N. Gerson, Minal A. Barve, Bryone Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah

Research output: Contribution to journalMeeting Abstractpeer-review


Covalent Bruton tyrosine kinase inhibitors (BTKi) have been an important advancement of Waldenström macroglobulinemia (WM) treatment, but they are non-curative, and treatment effectiveness can be limited by intolerance and resistance. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi.
We report the first sizeable cohort of WM patients from BRUIN.
Patients with previously treated B-cell malignancies, including WM, were eligible for pirtobrutinib monotherapy in dose-escalation/expansion portions of BRUIN. Key endpoints: investigator-assessed ORR and DoR, per modified IWWM6 criteria, and safety. Major response was CR, very good partial response (VGPR)/PR. The responseevaluable cohort was relapsed/refractory (R/R) WM patients in phase 1/2 who had undergone first response assessment /discontinued therapy. The safety cohort was patients with B-cell malignancies receiving at least one pirtobrutinib monotherapy dose (n=725). Data cut: 31 January 2022.
Of 78 WM patients(median age: 68 [42-84] years), the median number of prior therapies was 3 (1-11). 66 (85%) patients had received chemotherapy+anti-CD20 antibody (CIT), 61 (78%) ≥1 prior BTKi (≥2: 13/61, 21%), and 50
(64%) CIT+BTKi. Of 61 patients who received ≥1 prior BTKi, 40 (66%) discontinued BTKi due to disease progression. 91% (71/78) received the recommended phase 2 dose (200 mg once daily) as starting dose. The major
response rate for 72 response-evaluable patients was 68% (95%CI, 56-79); 17 VGPRs (24%), 32 PRs (44%). At a median response follow-up time of 7.7 months, median DoR among 49 responding patients was not reached (95%CI, 10-NE); 6-month estimated DoR rate: 86% (95%CI, 69-94). Of 55 response-evaluable patients who had received ≥1 prior BTKi, the major response rate was 64% (95%CI, 50-76); 13 VGPRs (24%), 22 PRs (40%) (median DoR also not reached [95%CI, 8-NE], 6-month estimated DoR rate: 83% [95%CI, 60-93]). Of 60 response-evaluable patients who had received CIT, the major response rate was 68% (95%CI, 55-80); 13 VGPRs (22%), 28 PRs (47%). Of 44 response-evaluable patients who had received CIT+BTKi, the major response rate was 64% (95%CI, 48-78); 9 VGPRs (21%), 19 PRs (43%). In the safety cohort of all pirtobrutinib-treated patients with B-cell malignancies (n=725), the most frequent TEAEs were fatigue (26%), diarrhea (22%), contusion (19%); most frequent Grade≥3 TEAE: neutropenia (20%). Low rates of Grade≥3 TEAEs hypertension (3%), hemorrhage (2%), atrial fibrillation/flutter (1%) were observed. Overall, 15 (2%) patients discontinued due to treatment-related AE.
Pirtobrutinib was highly active in WM patients, regardless of prior therapy. Pirtobrutinib was well tolerated with low discontinuation rates.
Original languageEnglish
Pages (from-to)557-560
Number of pages4
Issue numberSupplement 1
Publication statusPublished - 15 Nov 2022


  • Bruton’s tyrosine kinase inhibitor (BTKi)
  • Waldenstrom’s macroglobulinemia
  • Clinical trial
  • Non-Hodgkin’s lymphoma


Dive into the research topics of 'Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study'. Together they form a unique fingerprint.

Cite this